Key Takeaways
- • High-testosterone hedge fund managers underperform low-testosterone counterparts by 5.8% annually after risk adjustment, according to research from the University of Central Florida and Singapore Management University covering 3,228 male fund managers across 1,901 firms from 1994–2015.
- • Testosterone exposure—measured via facial width-to-height ratio (fWHR)—correlates with excessive trading frequency, concentration in high-risk securities, and reluctance to exit losing positions, creating systematic performance drag independent of fund size, age, or liquidity factors.
- • High-testosterone managers exhibit elevated operational risk, with greater likelihood of regulatory disclosures and fund termination compared to lower-testosterone peers.
- • Paradoxically, high-testosterone investors demonstrate attraction to high-testosterone-managed funds, suggesting behavioral alignment between manager and investor testosterone levels drives capital allocation despite inferior returns.
Summary
A comprehensive academic study has quantified a significant performance penalty associated with elevated testosterone levels among hedge fund managers. Researchers Yan Lu and Melvyn Teo examined performance data spanning two decades (January 1994–December 2015) across 3,228 male fund managers operating within 1,901 investment firms. Using facial width-to-height ratio (fWHR) as a proxy for testosterone exposure—a metric validated in prior research as correlating with pubertal testosterone exposure in adults—the researchers identified a consistent performance deficit among higher-testosterone managers.
The magnitude of underperformance is material: managers with elevated testosterone levels underperformed their low-testosterone counterparts by 5.8% per year after adjusting for risk factors. Critically, this performance gap persists after controlling for fund-specific variables including illiquidity, fund age, and asset under management, indicating the underperformance stems from manager behavior rather than structural fund characteristics. The authors attribute this performance drag to three behavioral patterns: excessive trading frequency, concentration in high-risk, high-potential-return equity positions, and a demonstrated reluctance to realize losses on deteriorating positions.
Beyond returns, the research documents elevated operational risk among high-testosterone managers. These managers disclosed regulatory actions at higher rates and experienced higher fund termination rates relative to low-testosterone peers, suggesting behavioral patterns that generate compliance and reputational friction alongside portfolio underperformance.
An unexpected finding emerged regarding investor behavior: investors exhibiting elevated testosterone levels themselves demonstrated greater capital allocation toward high-testosterone-managed funds, despite their documented lower returns. The authors characterize this pattern as behavioral mirroring, whereby the aggressive trading style and risk profile of high-testosterone funds appeal to similarly-inclined investors. This dynamic suggests that performance-based capital flows may not fully correct the market for the identified underperformance, as risk-seeking investors accept lower alpha in exchange for trading behavior alignment with their own risk preferences.
The magnitude of underperformance is material: managers with elevated testosterone levels underperformed their low-testosterone counterparts by 5.8% per year after adjusting for risk factors. Critically, this performance gap persists after controlling for fund-specific variables including illiquidity, fund age, and asset under management, indicating the underperformance stems from manager behavior rather than structural fund characteristics. The authors attribute this performance drag to three behavioral patterns: excessive trading frequency, concentration in high-risk, high-potential-return equity positions, and a demonstrated reluctance to realize losses on deteriorating positions.
Beyond returns, the research documents elevated operational risk among high-testosterone managers. These managers disclosed regulatory actions at higher rates and experienced higher fund termination rates relative to low-testosterone peers, suggesting behavioral patterns that generate compliance and reputational friction alongside portfolio underperformance.
An unexpected finding emerged regarding investor behavior: investors exhibiting elevated testosterone levels themselves demonstrated greater capital allocation toward high-testosterone-managed funds, despite their documented lower returns. The authors characterize this pattern as behavioral mirroring, whereby the aggressive trading style and risk profile of high-testosterone funds appeal to similarly-inclined investors. This dynamic suggests that performance-based capital flows may not fully correct the market for the identified underperformance, as risk-seeking investors accept lower alpha in exchange for trading behavior alignment with their own risk preferences.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.